216 related articles for article (PubMed ID: 2944378)
1. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
[TBL] [Abstract][Full Text] [Related]
2. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
3. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
[TBL] [Abstract][Full Text] [Related]
4. [Molecular markers of hemostatic-mechanisms--plasmin-alpha 2 plasmin inhibitor complex].
Kawai Y; Watanabe K
Rinsho Byori; 1989 Mar; 37(3):248-55. PubMed ID: 2526263
[No Abstract] [Full Text] [Related]
5. Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo.
Draxler DF; Zahra S; Goncalves I; Tran H; Hanafi G; Ho H; Keragala CB; Ilich A; Key NS; Myles PS; Medcalf RL
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):172-179. PubMed ID: 33443933
[TBL] [Abstract][Full Text] [Related]
6. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
[TBL] [Abstract][Full Text] [Related]
7. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Kario K; Matsuo T
Atherosclerosis; 1993 Nov; 103(2):131-8. PubMed ID: 8292090
[TBL] [Abstract][Full Text] [Related]
8. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
9. Increased urokinase and consumption of α
Longstaff C; Locke M
J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.
Takahashi H; Takizawa S; Hanano M; Tatewaki W; Nagasaki Y; Sasagawa Y; Shibata A
Tohoku J Exp Med; 1987 Dec; 153(4):295-302. PubMed ID: 2964745
[TBL] [Abstract][Full Text] [Related]
11. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Booth NA; Bennett B
Br J Haematol; 1984 Apr; 56(4):545-56. PubMed ID: 6201189
[TBL] [Abstract][Full Text] [Related]
12. Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
Takahashi H; Tatewaki W; Nakamura T; Hanano M; Wada K; Shibata A
Am J Hematol; 1989 Jan; 30(1):14-21. PubMed ID: 2521276
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Wada H; Kaneko T; Ohiwa M; Tanigawa M; Hayashi T; Tamaki S; Minami N; Deguchi K; Suzuki K; Nakano T
Am J Hematol; 1993 Oct; 44(2):101-5. PubMed ID: 8266913
[TBL] [Abstract][Full Text] [Related]
14. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
[TBL] [Abstract][Full Text] [Related]
15. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
[TBL] [Abstract][Full Text] [Related]
16. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
17. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
Gram J; Munkvad S; Leebeek FW; Kluft C; Jespersen J
Coron Artery Dis; 1993 Apr; 4(4):371-7. PubMed ID: 8261210
[TBL] [Abstract][Full Text] [Related]
18. [Coagulation and fibrinolysis parameters in disseminated intravascular coagulation (DIC)].
Nakagawa T; Saito H; Watanabe Y; Sato M; Murakawa E
Rinsho Byori; 1991 Mar; 39(3):309-14. PubMed ID: 1828842
[TBL] [Abstract][Full Text] [Related]
19. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation.
Wada H; Minamikawa K; Wakita Y; Nakase T; Kaneko T; Ohiwa M; Tamaki S; Deguchi K; Shirakawa S; Hayashi T
Am J Hematol; 1993 Oct; 44(2):85-8. PubMed ID: 8266924
[TBL] [Abstract][Full Text] [Related]
20. [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer].
Oikawa T; Muramatsu Y; Akashi S; Usui N
Nihon Jinzo Gakkai Shi; 1997 Mar; 39(2):144-9. PubMed ID: 9134831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
